MorphoSys (ETR:MOR) has been given a €130.00 ($151.16) target price by analysts at JPMorgan Chase & Co. in a research report issued on Wednesday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 0.78% from the stock’s current price.
A number of other research analysts have also recently weighed in on MOR. Deutsche Bank set a €129.00 ($150.00) price target on shares of MorphoSys and gave the company a “buy” rating in a research report on Friday, December 6th. Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the company a “neutral” rating in a research report on Tuesday, November 19th. HSBC set a €81.00 ($94.19) price target on shares of MorphoSys and gave the company a “sell” rating in a research report on Friday, August 16th. Independent Research set a €110.00 ($127.91) price target on shares of MorphoSys and gave the company a “neutral” rating in a research report on Friday, November 1st. Finally, Royal Bank of Canada set a €130.00 ($151.16) price target on shares of MorphoSys and gave the company a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of €119.86 ($139.37).
Shares of MOR stock opened at €129.00 ($150.00) on Wednesday. The stock has a market cap of $4.09 billion and a price-to-earnings ratio of -42.41. The company has a quick ratio of 7.63, a current ratio of 7.80 and a debt-to-equity ratio of 9.78. MorphoSys has a fifty-two week low of €79.70 ($92.67) and a fifty-two week high of €118.90 ($138.26). The firm’s 50 day moving average price is €105.57 and its two-hundred day moving average price is €100.09.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: Certificate of Deposit (CD) For Risk Adverse Investors?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.